Spero Therapeutics IncNASDAQ:SPRO
- LAST PRICE1.3100
- TODAY'S CHANGE (%)0.0300 (2.3437%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close1.2800 / 1.2800
- Day Range
- 52 Week Range
- Volume105,441
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SPRO |
|---|---|---|
| 09:32 ET | 1107 | 1.28 |
| 09:38 ET | 1013 | 1.29 |
| 09:39 ET | 5790 | 1.29 |
| 09:41 ET | 1350 | 1.2817 |
| 09:48 ET | 250 | 1.2999 |
| 09:50 ET | 500 | 1.295 |
| 09:52 ET | 400 | 1.3 |
| 09:56 ET | 14599 | 1.29 |
| 10:03 ET | 1000 | 1.29 |
| 10:10 ET | 5913 | 1.2799 |
| 10:12 ET | 2436 | 1.28 |
| 10:14 ET | 492 | 1.2799 |
| 10:15 ET | 13505 | 1.3 |
| 10:19 ET | 300 | 1.3 |
| 10:21 ET | 500 | 1.3 |
| 10:35 ET | 139 | 1.33 |
| 10:39 ET | 850 | 1.33 |
| 10:42 ET | 100 | 1.335 |
| 10:46 ET | 900 | 1.33 |
| 10:50 ET | 1100 | 1.35 |
| 10:51 ET | 2162 | 1.335 |
| 10:53 ET | 200 | 1.3306 |
| 10:55 ET | 100 | 1.3301 |
| 11:02 ET | 1300 | 1.33 |
| 11:04 ET | 2000 | 1.325 |
| 11:18 ET | 100 | 1.34 |
| 11:20 ET | 100 | 1.34 |
| 11:22 ET | 1136 | 1.35 |
| 11:26 ET | 180 | 1.34 |
| 11:27 ET | 799 | 1.335 |
| 11:38 ET | 310 | 1.34 |
| 11:42 ET | 2200 | 1.33 |
| 11:49 ET | 500 | 1.33 |
| 11:51 ET | 600 | 1.3301 |
| 11:58 ET | 300 | 1.33 |
| 12:00 ET | 1330 | 1.3302 |
| 12:02 ET | 100 | 1.335 |
| 12:03 ET | 440 | 1.34 |
| 12:16 ET | 200 | 1.34 |
| 12:18 ET | 200 | 1.34 |
| 12:23 ET | 5400 | 1.33 |
| 12:34 ET | 300 | 1.33 |
| 12:38 ET | 100 | 1.33 |
| 12:43 ET | 100 | 1.33 |
| 12:48 ET | 200 | 1.34 |
| 01:03 ET | 100 | 1.33 |
| 01:06 ET | 678 | 1.331 |
| 01:08 ET | 100 | 1.33 |
| 01:17 ET | 100 | 1.3399 |
| 01:32 ET | 100 | 1.33 |
| 01:37 ET | 1600 | 1.33 |
| 01:42 ET | 200 | 1.33 |
| 01:51 ET | 700 | 1.32 |
| 01:53 ET | 250 | 1.33 |
| 01:57 ET | 314 | 1.32 |
| 02:00 ET | 700 | 1.32 |
| 02:24 ET | 1197 | 1.32 |
| 02:26 ET | 1600 | 1.32 |
| 02:27 ET | 100 | 1.32 |
| 02:33 ET | 100 | 1.32 |
| 02:36 ET | 100 | 1.325 |
| 02:47 ET | 1383 | 1.31 |
| 03:02 ET | 1000 | 1.3278 |
| 03:05 ET | 600 | 1.31 |
| 03:09 ET | 100 | 1.31 |
| 03:14 ET | 444 | 1.31 |
| 03:16 ET | 500 | 1.31 |
| 03:25 ET | 661 | 1.31 |
| 03:27 ET | 100 | 1.3 |
| 03:30 ET | 1100 | 1.3 |
| 03:32 ET | 136 | 1.3 |
| 03:34 ET | 100 | 1.3016 |
| 03:43 ET | 200 | 1.3 |
| 03:50 ET | 3571 | 1.3 |
| 03:52 ET | 600 | 1.3 |
| 03:56 ET | 200 | 1.3 |
| 03:57 ET | 100 | 1.305 |
| 03:59 ET | 6321 | 1.31 |
Sep 4, 2024
Spero Therapeutics to Present at Upcoming September Investor Conferences, from 4:05PM ET on Wednesday Sep 04, 2024 by Dow Jones
4:05PM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Spero Therapeutics Inc | 74.0M | 4.1x | --- |
CytomX Therapeutics Inc | 96.1M | 8.8x | --- |
Aytu Biopharma Inc | 15.4M | -0.9x | --- |
Fortress Biotech Inc | 44.9M | -0.4x | --- |
2Seventy Bio Inc | 242.1M | -1.6x | --- |
Cannabis Bioscience International Holdings Inc | 8.3M | 0.0x | --- |
Company Information
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting.
Contact Information
- Headquarters
- 675 Massachusetts Ave Ste 14CAMBRIDGE, MA, United States 02139-3309
- Phone
- 857-242-1600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Ankit Mahadevia
- President, Chief Executive Officer, Director
- Satyavrat Shukla
- Chief Financial Officer and Chief Business Officer
- Esther Rajavelu
- Chief Operating Officer
- Timothy Keutzer
- Chief Medical Officer
- Kamal Hamed
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $74.0M |
|---|---|
Revenue (TTM) | $118.5M |
Shares Outstanding | 54.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.62 |
EPS | $0.32 |
Book Value | $2.02 |
P/E Ratio | 4.1x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | 4.2x |
Operating Margin | 13.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
